Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sling Therapeutics, Inc.

News headline image
Sling Therapeutics to Present Data from Phase 2b/3 LIDS Trial of Oral IGF-1R Inhibitor Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium
From Sling Therapeutics, Inc.
Via Business Wire
News headline image
Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease
From Sling Therapeutics, Inc.
Via Business Wire
News headline image
Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
From Sling Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.